American journal of obstetrics and gynecology
-
Am. J. Obstet. Gynecol. · Dec 2015
Randomized Controlled Trial Multicenter StudyDoes 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
We sought to determine if maternal weight or body mass index (BMI) modifies the effectiveness of 17-alpha hydroxyprogesterone caproate (17OHP-C). ⋯ The effectiveness of 17OHP-C is modified by maternal weight and BMI, and treatment does not appear to reduce the rate of PTB in women who are obese or have a weight >165 lb. This finding may be due to subtherapeutic serum levels in women with increased BMI or weight. Studies of adjusted-dose 17OHP-C in women who are obese or who weigh >165 lb are warranted, and current recommendations regarding the uniform use of 17OHP-C regardless of maternal BMI and weight may deserve reassessment.